Pomalidomide

Pomalidomide
Clinical data
Trade names	Pomalyst, others
AHFS/Drugs.com	Monograph
MedlinePlus	a613030
License data	US DailyMed: Pomalidomide;
Pregnancy; category	AU: X (High risk); ;
Routes of; administration	By mouth
ATC code	L04AX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C3 (Immunosuppressive drugs); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	73% (at least)
Protein binding	12–44%
Metabolism	Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
Elimination half-life	7.5 hours
Excretion	Urine (73%), faeces (15%)
Identifiers
	IUPAC name 4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3-dione;
CAS Number	19171-19-8;
PubChem CID	134780;
IUPHAR/BPS	7348;
DrugBank	DB08910;
ChemSpider	118785;
UNII	D2UX06XLB5;
KEGG	D08976;
ChEMBL	ChEMBL43452;
CompTox Dashboard (EPA)	DTXSID40893458 ;
ECHA InfoCard	100.232.884
Chemical and physical data
Formula	C13H11N3O4
Molar mass	273.248 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C1C=2C=CC=C(N)C2C(=O)N1C3C(=O)NC(=O)CC3;
	InChI InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18); Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N;

Pomalidomide, sold under the brand name Pomalyst among others, is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. It inhibits angiogenesis, the formation of new blood vessels.

Pomalidomide was approved for medical use in the United States in February 2013, and in the European Union in August 2013. It is available as a generic medication.